Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
A Phase II Study of Platinum-doublet Chemotherapy in Combination With Nivolumab as First-line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic G3 Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
This PHASE2 trial investigates Gastroenteropancreatic Neuroendocrine Tumor and Neuroendocrine Neoplasm and is currently completed. Grupo Espanol de Tumores Neuroendocrinos leads this study, which shows 14 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — May 2020 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Espanol de Tumores Neuroendocrinos
For direct contact, visit the study record on ClinicalTrials.gov .